Q3 2018 13F Holders as of 30 Sep 2018
-
Type / Class
-
Equity / Common Stock
-
Shares outstanding
-
74,361,296
-
Total 13F shares
-
25,454,371
-
Share change
-
-387,218
-
Total reported value
-
$218,398,586
-
Price per share
-
$8.58
-
Number of holders
-
57
-
Value change
-
-$3,359,100
-
Number of buys
-
30
-
Number of sells
-
16
Institutional Holders of Corvus Pharmaceuticals, Inc. - Common Stock (CRVS) as of Q3 2018
As of 30 Sep 2018,
Corvus Pharmaceuticals, Inc. - Common Stock (CRVS) was held by
57 institutional
shareholders
that filed Form 13F with the SEC.
Together, they reported ownership of
25,454,371 shares.
The largest 10 holders included
ORBIMED ADVISORS LLC, Novo Holdings A/S, ADAMS STREET PARTNERS LLC, FMR LLC, PRICE T ROWE ASSOCIATES INC /MD/, BVF INC/IL, BlackRock Inc., Vanguard Group Inc, COWEN INC., and Rock Springs Capital Management LP.
This page lists
57
institutional shareholders reporting positions in this security
for the Q3 2018 filing period.
| Investor |
Option |
Weight % |
Change % |
Value $ |
* Price
|
Shares |
Share Change |
Activity |
Report Period |
* Reported Price is the price of the security as of the portfolio date. This value is significant in that it is the last known price at which the security was still held.
An asterisk sign (*) next to the price indicates that the price is likely invalid.